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JanusMatrix, a newly developed algorithm by EpiVax, Inc, identifies cross-reactive T cell epitopes by matching 
the T cell receptor (TCR)-accessible amino acids (the TCR face) of peptides that bind the same human 
leukocyte antigen (HLA) [1]. Taking into both HLA binding and TCR contact account, JanusMatrix is uniquely 
able to compare T cell epitope conservation between protein sequences from bacterial and viral organisms that 
make up the human gut microbiome, autologous proteins from the human genome, and human viral and 
bacterial pathogens. 
 
We recently discovered that pathogens might escape human immune response by mutating their epitopes to 
present “human-like” amino acid sequences to TCR when displayed on antigen-presenting cells [2]. We 
hypothesized that such “human-like” T cell epitopes contained in pathogens may trigger autologous regulatory T 
cells (Tregs), actively suppress immune response to themselves, thus improving their ability to survive in the 
host. We have used JanusMatrix to identify such “human-like” pathogen sequences that both bind HLA and 
share the same TCR-face patterns as human proteins.  
 
In a large scale analysis of viruses that infect humans, we found that chronic viruses that establish persistent 
infection in human (such as Epstein-Barr, Herpes Simplex Virus and Cytomegalovirus) contain a significantly 
higher number of T cell epitopes that are cross-conserved (at the TCR face) with human proteins than viruses 
that do not establish chronic infection (such as Ebola and Marburg) [3]. Using JanusMatrix, we identified human-
like T cell epioteps in H7N9 influenza hemagglutinin (HA) protein [4]. A promiscuous T cell epitope from H7N9 
HA expanded Tregs and suppressed responses to other H7N9 peptides. This may explain the low titer of H7N9 
HA inhibiting antibody responses and diminished seroconversion rates. Depletion the Treg-activating epitope 
increased antibody titers by 5 fold and B cell response by 20 fold (Unpublished). We also identified a “human-
like” HCV T cell epitope, HCV_G1_p7_794, induced a marked increase of Tregs in PBMC derived from HCV-
infected patients [5]. In HIV-1 Env, we found a human-like epitope that shares a TCR-face with a large number 
of human leukocyte antigen (HLA) class I molecule sequences. This highly conserved epitope is found in both 
the HIV-1 E and B Env antigens used in the ‘moderately effective’ HIV RV144 trial. It was found that this HIV 
Env-derived T cell epitope trigger functional Treg responses in HIV negative individuals. All these results 
suggest that JanusMatrix tool opens up a new window on the networks of cross-reactive T cell epitopes in 
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